# Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer

> **NCT04425239** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute, Naples** · enrollment: 151 (actual)

## Conditions studied

- Colorectal Cancer Stage IV

## Interventions

- **DRUG:** Panitumumab
- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT04425239
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-21
- **Primary completion:** 2021-07-02
- **Final completion:** 2022-04-03
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04425239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04425239, "Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04425239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*